Human Papillomavirus Vaccination and Human Papillomavirus-Related Cancer Rates.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 Sep 2024
Historique:
medline: 5 9 2024
pubmed: 5 9 2024
entrez: 5 9 2024
Statut: epublish

Résumé

To inform the design and implementation of targeted interventions to reduce the future burden of human papillomavirus (HPV)-related cancers in Texas, it is necessary to examine the county and health service region (HSR) levels of (1) the proportion of children and teenagers aged 9 to 17 years who initiated and were up to date for HPV vaccination series and (2) HPV-related cancer incidence rates (IRs). To evaluate temporal trends and geospatial patterns of HPV vaccination initiation and up-to-date status as well as HPV-related cancer rates at county and HSR levels in Texas. This population-based cross-sectional study used data from the Texas Immunization Registry, the National Cancer Institute's Surveillance, Epidemiology, and End Results Program database, and Texas Department of State Health Services annual population counts from 2006 to 2022. The analysis of HPV vaccination rates was conducted among children and teenagers aged 9 to 17 years; the analysis of HPV-related cancer rates was conducted among adults aged 20 years and older. Data were extracted between June and July 2023 and statistical analysis was performed from February to April 2024. HPV vaccination initiation and up-to-date status rates and HPV-related cancer IR at county and HSR levels. A total of 32 270 243 children and teenagers (65.8% female individuals and 34.2% male individuals) and 22 490 105 individuals aged 20 years and older (50.7% female individuals and 49.3% male individuals) were included. The mean 2021 to 2022 county-level HPV vaccination series initiation estimates ranged from 6.3% to 69.1% for female and from 7.0% to 77.6% for male children and teenagers aged 9 to 17 years. County-level vaccination up-to-date estimates were generally lower compared with those of initiation estimates and ranged from 1.6% to 30.4% for female and from 2.1% to 34.8% for male children and teenagers. The pattern of HPV vaccination rates stratified by sex were similar across counties and HSRs. The age-adjusted annual HPV-related cancer IR by county for years 2016 to 2020 ranged from 0 to 154.2 per 100 000 for female individuals and from 0 to 60.1 per 100 000 for male individuals. The counties located in North Texas, HSRs 2/3 and 4/5N, had lower HPV vaccination rates and higher IRs of HPV-related cancers for both female and male individuals compared with other regions. In this study, the incidence of HPV-related cancers varied widely across the counties and HSRs of Texas. More counties in North Texas, HSRs 2/3 and 4/5N, had higher IRs of HPV-related cancers and a lower proportion of HPV vaccination rates than counties in other regions. Designing and implementing targeted interventions to increase uptake and completion of HPV vaccination series across counties with low HPV vaccination rates may help to reduce future the burden of HPV-related cancers.

Identifiants

pubmed: 39235811
pii: 2823251
doi: 10.1001/jamanetworkopen.2024.31807
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2431807

Auteurs

Victor Adekanmbi (V)

Center for Interdisciplinary Research in Women's Health, School of Medicine, The University of Texas Medical Branch, Galveston.
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston.

Itunu Sokale (I)

Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston.
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Fangjian Guo (F)

Center for Interdisciplinary Research in Women's Health, School of Medicine, The University of Texas Medical Branch, Galveston.
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston.

Jessica Ngo (J)

School of Medicine, The University of Texas Medical Branch, Galveston.

Thao N Hoang (TN)

Institute for Translational Sciences, The University of Texas Medical Branch, Galveston.

Christine D Hsu (CD)

Center for Interdisciplinary Research in Women's Health, School of Medicine, The University of Texas Medical Branch, Galveston.
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston.

Abiodun Oluyomi (A)

Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston.
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Abbey B Berenson (AB)

Center for Interdisciplinary Research in Women's Health, School of Medicine, The University of Texas Medical Branch, Galveston.
Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH